ONCAlert | 2018 ASCO Annual Meeting

Dr. Sant P. Chawla on Trabectedin for the Treatment of Mesenchymal Chondrosarcoma

Sant P. Chawla, MD
Published Online: 11:32 PM, Thu November 5, 2015

Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.

Mesenchymal chondrosarcoma is a very rare disease that often has a lot of potential to metastasize, Chawla says.

In this small study of fewer than 20 patients, some patients had previously failed standard chemotherapy and trabectedin did control disease in some of those patients for up to two years.

Moving forward, Chawla says, there will first need to be collaboration between institutions and pharmaceutical companies to determine if similar results have been seen before.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.